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Abstract
Pulmonary involvement is common in sarcoidosis, an immune-
mediated inflammatory disorder that is characterized by non-
caseating granulomas in tissue. Sarcoid patients with advanced
pulmonary disease, especially end-stage pulmonary fibrosis, risk
developing pulmonary hypertension (World Health Organization
group III pulmonary hypertension secondary to hypoxic lung disease).
Increased levels of endothelin (ET)-1 in plasma and broncho-
alveolar lavage of some sarcoid patients suggest that ET-1 may be
driving pulmonary fibrosis and sarcoidosis-associated pulmonary
hypertension. Although a relationship between raised levels of ET-
1 and clinical phenotype is yet to be identified, early evidence from
studies of ET-1 blockade with drugs such as bosentan is
encouraging. Such therapy possibly could be combined with
standard anti-inflammatory agents to improve outcome.
Introduction
Sarcoidosis is a systemic granulomatous disease of unknown
aetiology that is characterized by the presence of non-
caseating granulomas in tissue. Although many patients
experience disease resolution, in about 25% of cases the
disease has a progressive, chronic course [1]. Because the
cause of sarcoidosis remains unknown, diagnosis is
established when clinical and radiographic findings are
supported by histological evidence of noncaseating
granulomas in biopsied tissue. Importantly, because there are
several conditions that may involve the development of
noncaseating granulomatous lesions, accurate diagnosis
requires exclusion of these causes of granulomatous disease
(which can be a confounding factor for diagnosis) and the
presence of noncaseating granulomatous in at least two
organs. Importantly, it is almost impossible to be sure that the
condition is in fact sarcoidosis.
Sarcoidosis is a classic multisystem disease, which can
affect the heart, skin (as in lupus pernio), liver, eyes, lymph
nodes, salivary glands and, in particular, the respiratory
tissues. Pulmonary involvement is common in sarcoid patients
and may contribute to deteriorating lung function and the
eventual development of end-stage pulmonary fibrosis [2].
The chest roentgenogram of patients with sarcoidosis includes
those with interstitial lung disease with adenopathy (stage II),
interstitial lung disease (stage III), or fibrosis (stage IV).
Patients with advanced pulmonary disease, with vital
capacities of less than 60% predicted, or with extensive
interstitial lung disease or fibrosis (stages II, III and IV) are
prone to pulmonary hypertension (PH) and cor pulmonale. This
review focuses on sarcoid patients with persistent chronic
pulmonary disease. It explores the role of the endothelin
system in the pathophysiology of pulmonary fibrosis and
discusses the therapeutic potential of endothelin blockade.
Pathophysiology of sarcoidosis: current opinion
The precise cause of sarcoidosis is yet to be elucidated.
However, current opinion holds that the disease is triggered
by exposure to an antigen, such as Propionibacterium acnes,
or a number of antigens [3,4]. Although the precise identity of
the antigen(s) remains elusive, the subsequent activation of a
complicated cascade of cytokines is unequivocal. Antigenic
exposure leads to T-cell activation and an increase in CD4+
helper T cells. A cascade of proinflammatory cytokines, inclu-
ding IL-2, interferon-γ, IL-12, IL-18 and tumour necrosis factor
(TNF)-α, is released, which leads to inflammation and even-
tually fibrosis [5] (Figure 1). In a series of bronchoalveolar
lavage (BAL) studies conducted in the 1970s, it was shown
that in patients with sarcoidosis there is an influx of CD4+
cells [6], suggesting that elimination of these cells would be
sufficient to cure sarcoidosis. However, cyclosporine is not
effective in sarcoidosis, and whereas the influx of CD4+ cells
is among the initiating events in sarcoidosis, these cells are
not important in longstanding, persistent, fibrotic forms of the
disease.
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One of the confounding aspects of sarcoidosis is that in
many people the condition will resolve spontaneously and in
many cases the initiation of treatment influences the likeli-
hood of long-term treatment being required. As a conse-
quence, approximately half of sarcoidosis patients never need
therapy and about one-quarter require years of therapy. The
ACCESS (A Case Control Etiologic Study of Sarcoidosis)
study [1] evaluated a subset of patients seen within 6 months
of diagnosis and 2 years later. In all, 205 sarcoidosis patients
were analyzed. Use of systemic therapy within the first
6 months after diagnosis appeared to be strongly associated
with continued use of therapy 2 years later. Approximately
25% of all patients studied developed chronic persistent
sarcoidosis. In these patients, there is evidence that IL-8 and
TNF-α are among the most important mediators of inflam-
mation and fibrosis [5].
TNF-α is a potent cytokine that has been implicated in many
immune-mediated disorders. One study, in which patients
with sarcoidosis were treated for 2 years with methotrexate, a
nonspecific inhibitor of TNF-α, showed that 60% to 80% of
patients with pulmonary disease responded to therapy [7].
Correspondingly high response rates of between 60% and
70% were observed in patients with brain, eye and skin
involvement. Evidence for the efficacy of methotrexate in
sarcoidosis was also demonstrated in a subsequent
randomized, placebo-controlled, double-blind trial in patients
with acute pulmonary disease [8]. In this study patients
received either methotrexate or placebo in addition to
standard corticosteroid therapy (prednisone), which also
blocks cellular release of TNF-α. Over a 12-month period,
patients in the methotrexate arm of the study required
significantly lower doses of steroids than did those who were
randomly assigned to placebo. These steroid-sparing effects
of methotrexate were evident after the first 6 months when
placebo-treated patients required twice as much steroid
therapy to prevent relapse as those given methotrexate.
The role of endothelin in sarcoidosis and
rationale for endothelin blockade
In scleroderma the role of endothelin (ET)-1 in pulmonary
fibrosis and associated complications such as PH is well
documented [9-11]; in contrast, less is known about the
importance of ET-1 in sarcoidosis. Sofia and coworkers [12]
published data showing that ET-1 was elevated in the urine of
patients with sarcoidosis but not in those with idiopathic
pulmonary fibrosis (IPF). However, in their study no difference
was observed in plasma ET-1 levels between sarcoid patients,
IPF patients, and healthy control individuals. This finding is at
variance with the large body of evidence showing that IPF
patients have significantly raised plasma ET-1 levels [13,14],
and insufficient clinical correlative information was available.
More recently, Letizia and colleagues [15] showed that plasma
ET-1 levels were raised in patients with sarcoidosis compared
with those in healthy control individuals. Sarcoid patients also
had raised levels of serum angiotensin-converting enzyme, a
finding consistent with those of many other studies [16,17],
and a raised erythrocyte sedimentation rate. Interestingly, in
patients who went into remission following successful
corticosteroid therapy, ET-1 levels decreased and other
parameters of disease activity normalized.
Further evidence to suggest that ET-1 may be involved in
sarcoidosis came from assessments of ET-1 levels in BAL
specimens. BAL is a standard method for assessing inter-
stitial lung disease and it is a useful sampling procedure for
obtaining direct evidence of alveolar inflammation. Reichen-
berger and colleagues [18] examined ET-1 levels in BAL
specimens from patients with various lung conditions, inclu-
ding chronic obstructive pulmonary disease, IPF, scleroderma
and sarcoidosis. As expected, elevated ET-1 levels were
observed in patients with IPF and scleroderma but not in
those with chronic obstructive pulmonary disease or healthy
control individuals (Figure 2). Comparably high ET-1 levels to
those seen in scleroderma and IPF patients were also
observed in the patients with sarcoidosis.
Some of the best data on the likely importance of ET-1 in
sarcoidosis have come from a recent study in which ET-1
levels in BAL fluid were compared between 22 nonsmoking
sarcoid patients and 12 nonsmoking healthy control indivi-
duals [19]. Although the study did not document clinical
outcome in these patients, elevated ET-1 levels were
Figure 1
Inflammatory reaction of sarcoidosis. The initial response of
sarcoidosis is mediated by CD4 and APCs which release a large
number of cytokines. Over time, the granuloma can either resolve or go
on to form fibrosis. Fibrosis is associated with TNF, IL-8 and ET-1. Ag,
antigen; APC, antigen-presenting cell; ET, endothelin; HLA, human
leucocyte antigen; IFN, interferon; IL, interleukin; TNF, tumour necrosis
factor. Reproduced with permission from Baughman et al.: Tumour
necrosis factor in sarcoidosis and its potential for targeted therapy.
Biodrugs 2003, 17(6):425-431. © Wolters Kluwer Health [5].Page 3 of 7
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observed in approximately 25% (Figure 3). ET-1 levels also
correlated with the number of macrophages retrieved in the
BAL specimens (Figure 4).
Earlier work demonstrated that alveolar macrophages
harvested in BAL fluid from patients with IPF and sarcoidosis
were a primary source of ET-1, and that the supernatant from
these alveolar macrophages stimulated the growth of
fibroblasts [20]. In their study, Terashita and coworkers [19]
were also able to demonstrate that BAL supernatants from
the sarcoid patients led to increased fibroblast proliferation.
Moreover, in the presence of an ET-1 inhibitor, fibroblast
proliferation was blocked.
Thus, although data are currently limited, there is growing
evidence to suggest that levels of ET-1 in urine, plasma and
BAL fluid are increased in some, albeit not all, patients with
sarcoidosis. This raises intriguing questions about the clinical
significance of ET-1 in sarcoidosis and whether blockade of
ET-1 is a rational approach to therapy. Two case studies
provide some interesting insight into these questions.
Case 1: unexplained dyspnoea in sarcoidosis
Case 1 is that of a 45-year-old Caucasian female patient who
presented with severe dyspnoea 8 months after first seeing
her pulmonologist. The patient had initially developed a painful
rash (hives) on her legs and abdomen, which resolved with
steroids but recurred when therapy was withdrawn. A further
course of steroid therapy proved effective but the patient went
on to develop dyspnoea on exertion that progressively
Available online http://arthritis-research.com/content/9/S2/S8
Figure 2
Endothelin-1 levels in BAL fluid from patients with interstitial lung
disease, COPD, and control individuals. Levels of endothelin (ET)-1 in
bronchoalveolar lavage (BAL) fluid specimens taken from patients with
sarcoidosis (Sarc; n = 8), idiopathic pulmonary fibrosis (IPF; n = 9),
fibrosing alveolitis in systemic sclerosis (PSS; n = 13) and chronic
obstructive pulmonary disease (COPD; n = 8) were examined. A
heterogeneous group of 19 patients served as control individuals.
*Significantly higher than controls of COPD [18].
Figure 3
Endothelin-1 levels in bronchoalveolar lavage fluid (BAL) fluid in
sarcoid patients and healthy controls. Endothelin-1 levels were
measured by enzyme immunoassay and were corrected by albumin
concentration in recovered BAL fluid. The data represent values ±
standard error of the mean in both groups. *P < 0.05. Reproduced
with permission from Terashita et al. Respirology 2006. 
© Blackwell Publishing [19].
Figure 4
Histological evidence of endothelin-1 in macrophages from sarcoid
patients. Immunocytochemical detection of endothelin-1 in
bronchoalveolar lavage (BAL) cells from patients with sarcoidosis and
control individuals, using rabbit monoclonal antibody to human
endothelin-1. Cytoplasm of BAL cells from sarcoidosis was strongly
stained relative to controls. Immunostaining also demonstrated that
most of the immunopositive cells were macrophages. Reproduced with
permission from Terashita et al. Respirology 2006. © Blackwell
Publishing [19].worsened. Three months before referral for a second opinion,
the patient was hospitalized for severe dyspnoea.
On admission to hospital the chest radiograph showed
adenopathy and a soft pulmonary infiltrate, classified as stage
II sarcoid with lymph nodes and infiltrates but no fibrosis.
Granulomas were found on mediastinoscopy and sarcoidosis
was diagnosed. Aggressive therapy with 60 mg/day
prednisone improved symptoms, but any reduction in dosage
led to an exacerbation of dyspnoea. Eventually, prednisone
was tapered to 25 mg/day. By this stage the patient no
longer had a skin rash, the lungs were clear, and the chest
radiography showed minimal infiltrates and a marked
improvement from the pre-steroid film. Pulmonary function
tests (PFTs) revealed a forced expiratory volume in 1 s of
2.04 l and forced vital capacity of 2.52 l (84% of predicted),
but dyspnoea persisted.
Despite normal PFTs and no evidence of pulmonary fibrosis,
severe impairment was observed on the 6-min walk test
(6MWT), with the patient only managing to walk 300 m on
room air. Heart rate increased from 116 beats/min at baseline
to 140 beats/min after the 6MWT, arterial oxygen saturation
dropped to 77%, and the Borg dyspnoea index increased
from 3 to 10. PH with a right to left shunt was suspected and
subsequently confirmed by catheterization; right atrium
pressure was normal (10 mmHg), pulmonary artery pressure
(PAP) was 79/39 mmHg and pulmonary artery occlusion
pressure was 41 mmHg, but left ventricular end-diastolic
pressure was 12 mmHg.
The eventual diagnosis of PH in this patient with previously
unexplained, persistent dyspnoea is in accordance with
growing evidence suggesting that PH secondary to sarcoi-
dosis is relatively common. Indeed, among end-stage sarcoid
patients awaiting lung transplantation, PH is documented in
approximately 75% of cases, in which it is predictive of
increased mortality [21,22]. PH has also been documented in
approximately 50% of patients with advancing pulmonary
disease associated with sarcoidosis [23]. The mechanism of
PH in sarcoidosis appears to be multifactorial. Among the
possible causes are direct compression of the pulmonary
arteries, fibrotic destruction of the lung vasculature, hypoxia
and a pulmonary vasculopathy [24-26]. Direct vessel involve-
ment has been documented in some cases [26]. The PH can
respond to vasodilator drugs such as epoprostenol [27],
which emphasizes the importance of vascular disease in PH
associated with sarcoidosis.
PH in sarcoidosis can also be due to vasculitis. Extensive
vasculitis from the granulomatous involvement of sarcoidosis
usually leads to a presentation referred to as ‘necrotizing
sarcoid granulomatosis’ [28]. Whether this condition is an
extreme form of sarcoidosis or is a distinct entity is
controversial [29].
Case 2: worsening dyspnoea in
steroid-refractory sarcoidosis
Case 2 is that of a Caucasian female patient with biopsy-
confirmed sarcoidosis who experienced worsening dyspnoea
despite a 12-month course of prednisone. Over the 12-month
period, chest radiography revealed a worsening picture with
increased fibrotic changes in the upper lobes of the lung.
Cardiac catheterization revealed a PAP of 60 mmHg,
elevated pulmonary vascular resistance (PVR) of 253 dynes
and a pulmonary artery occlusion pressure of 8 mmHg, in
conjunction with normal left end-diastolic pressure. Treatment
with the dual endothelin receptor antagonist (ERA) bosentan
and the specific anti-TNF-α agent infliximab was initiated
[30]. Over a 3-year treatment period, PAP and PVR dropped
Arthritis Research & Therapy    Vol 9 Suppl 2 Baughman
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Table 1
Sarcoidosis before and after treatment: cardiac catheterization
data
January March  September 
2002 2003 2006
PAP systolic (mmHg) 60 42 37
PAP mean (mmHg) 36.7 24 19
CO (l/min) 7.8 10.2 6.9
PVR (dyn·s/cm5) 253 125 151
Bosentan dose (mg) 0 125  125 
twice daily twice daily
Shown are pretreatment and post-treatment cardiac catheterization
data in a patient with steroid-refractory sarcoidosis who was treated
with bosentan and infliximab. CO, cardiac output; PAP, pulmonary
artery pressure; PVR, pulmonary vascular resistance.
Figure 5
Sarcoidosis before and after treatment: chest radiography. Shown are
pretreatment (2003) and post-treatment (2006) chest radiographs in a
patient with steroid-refractory sarcoidosis treated with bosentan and
infliximab. Arrows indicate areas of infiltrates within both lung fields.
The infiltrates have improved between 2003 and 2006 with treatment
for the patient’s sarcoidosis.to the near normal range (Table 1). Commensurate improve-
ments were observed on chest radiography (Figure 5).
Preliminary clinical data with endothelin
receptor antagonists in sarcoidosis
As case 2 illustrates, ERAs such as bosentan appear to have
clinical benefit in sarcoidosis-associated PH. Although data
remain limited, other case studies support this encouraging
finding. Data from our centre on a small cohort of sarcoid
patients with persistent dyspnoea and elevated PAP
indicative of PH have shown that treatment with bosentan
reduces PAP [31] (Table 2).
The case of a 54-year-old male patient with sarcoidosis-
associated PH successfully treated with bosentan has also
been described [32]. This patient presented with stage II
pulmonary disease, exhibiting limited lung capacity and low
diffusing capacity for carbon monoxide but no evidence of
pulmonary fibrosis. Treatment with prednisone proved to be
of only limited clinical benefit, because the patient experienc-
ed recurrence of symptoms when the dosage was reduced to
20 mg/day. However, within 6 months of additional therapy
with bosentan, there was a marked reduction in PAP and an
even greater reduction in PVR. The mean PAP dropped from
55 mmHg before institution of bosentan to 23 at follow up,
whereas PVR dropped from 571 to 83 mmHg at follow up.
Additionally, during this period concomitant steroid therapy
was tapered to prednisone 7.5 mg/day.
Improvement in 6MWT following treatment with bosentan
was reported in the case of a 72-year-old black male patient
with secondary PH due to sarcoidosis [33]. Before treatment,
the patient had a forced vital capacity of 40% predicted, a
diffusing capacity for carbon monoxide of 46% predicted, a
PAP of 78 mmHg and a 6MWT distance of only 30 m.
Following treatment with bosentan 125 mg twice daily,
nifedipine, and prednisone, 6MWT distance increased to
320 m. Improvement in cardiac function was also observed
with a change in New York Heart Association functional class
from class IV to II after treatment.
Sarcoidosis patients are of course susceptible to PH for
other reasons. Cardiac sarcoidosis can lead to left heart
failure and ‘passive PH’ [34]. In addition, although none of the
patients included in our case series [31] exhibited evidence
of significant liver disease, liver involvement does occur and
may result in liver failure and portal hypertension, with
subsequent portopulmonary hypertension [35]. There are
also several reports in the literature of pulmonary veno-
occlusive disease [36,37] associated with sarcoidosis. Once
again, although our patients had radiological evidence of
pulmonary veno-occlusive disease, such as Kerley B lines or
septal lines and ground glass infiltrates [38], it is critical to
diagnose pulmonary veno-occlusive disease correctly in
these patients because they may develop potentially fatal
pulmonary oedema if they are given vasodilator therapy,
particularly epoprostenol [39]. Finally, sarcoidosis patients
may have profound hypoxaemia leading to PH, although in
our patient series the degree of PH and the fact that
pressures remained elevated despite oxygen therapy are
consistent with hypoxia not being a major contributing factor.
It could therefore be concluded that PH-associated
sarcoidosis fits into all five classes of the accepted World
Health Organization classification of PH [40]. Although PH
associated with sarcoidosis is officially grouped in World
Health Organization class 5, this is controversial and there
clearly are cases of PH associated with sarcoidosis that fit
more appropriately into other groups of this classification.
Conclusion
An expanding body of evidence suggests that PH is a
relatively common complication of sarcoidosis, not only in
patients with end-stage pulmonary fibrosis (stage IV), for
whom it is predictive of increased mortality, but also in those
with earlier stage pulmonary disease. There is also evidence
Available online http://arthritis-research.com/content/9/S2/S8
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Table 2
Improvement in PAP in patients with sarcoidosis-associated pulmonary hypertension following bosentan treatment
Initial mean  Follow-up mean  Pulmonary  Other 
Patient PAP (mmHg) PAP (mmHg) hypertension therapy sarcoidosis medications
1 73 41 Epoprostenol Prednisone, methotrexate, azathioprine, infliximab
2a 63 45 Bosentan Prednisone
3a 61 ND Bosentan, epoprostenol Prednisone, azathioprine
4 53 23 Amlodipine Prednisone, methotrexate
5 50 ND Bosentan Prednisone, methotrexate
6 38 36 Bosentan Prednisone, methotrexate, azathioprine
7 36 24 Bosentan Prednisone, methotrexate, infliximab
Shown are data demonstrating improvement in pulmonary artery pressure (PAP) following addition of bosentan to standard anti-inflammatory
therapy in a small cohort of patients with sarcoidosis-associated pulmonary hypertension. aPatient died. ND, not determined.that ET-1 levels are elevated in urine, plasma and BAL
specimens from sarcoid patients, albeit not in all. A relation-
ship between elevated ET-1 levels in body fluids, such as
plasma or BAL fluid, and clinical phenotype has yet to be
determined. However, outcomes from a small number of case
studies point to potential clinical benefit from dual endothelin
receptor antagonism with bosentan in sarcoidosis-associated
PH. This suggests that ET-1 may be an important driver of
pulmonary fibrosis and associated complications such as PH.
Future studies are planned to measure plasma and BAL fluid
levels of ET-1 in sarcoidosis patients, with and without PH.
Sarcoidosis is an immune-mediated inflammatory disorder,
with a wide range of clinical outcomes. Although the majority
of patients do well with no or minimal therapy, some patients
can develop chronic disease. Use of immunosuppressive
drugs can control this disease. In elucidating the role of ET-1
in sarcoidosis, it would be worthwhile to study further the
effects of immunomodulatory drugs on levels of ET-1.
Potentially suppressing the inflammatory response could have
a corresponding effect on ET-1 levels and on effects mediated
by ET-1. In one of the few studies in which ET-1 levels were
measured before and after corticosteroid therapy, plasma ET-
1 levels were seen to decrease in patients who went into
remission [14]. Additional studies are needed to confirm the
effects of immunomodulatory therapy on ET-1 levels as well as
to substantiate the extent to which augmenting standard anti-
inflammatory therapy with ERAs provides additional clinical
benefit in sarcoidosis-associated PH.
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